24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Multiple Sclerosis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
09:33
The less Intel, the better: Intel’s desperation could be Mobileye’s salvation
09:07
Fab38 freeze: Intel’s big manufacturing bet collides with harsh market reality
08:47
"How can an anti-Semitic politician who doesn’t recognize Israel be mayor of the world’s largest Jewish city?"
08:46
“The distinction between AI startups and non-AI startups will disappear entirely”
More stories
Buzz
Most popular
Daily
Weekly
1
Intel offers up to 19 salaries to laid-off employees if they don’t fight firings
2
Inside Intel's painful cuts: Who's being let go and why
3
Intel offloads $900 million in Mobileye shares to ease cash crunch
4
Intel CEO: "The strength, resilience and resolve of Intel Israel's team has no bounds"
5
Remote work’s dark side: The Soham Parekh story
More news
Multiple Sclerosis
2 stories about Multiple Sclerosis
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market
31.10.17
|
Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot